FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322770501> ?p ?o ?g. }

• W4322770501 endingPage "04" @default.
• W4322770501 startingPage "P6" @default.
• W4322770501 abstract "Abstract Triple negative breast cancer (TNBC) is one of the major subtypes of breast cancer, being associated with the lowest survival rate after metastasis occurs. TNBC patients face limited therapeutic options, relying mostly on a combination of chemotherapies (anthracycline, taxanes and cyclophosphamide). However, around 40% of patients treated with chemotherapy relapse due to onset of chemoresistance, contributing to the dismal survival of this aggressive subtype. Therefore, understanding the molecular mechanisms underlying chemoresistance is critical to identify better therapeutic target options. Guanosine triphosphate (GTP) is important for several biological processes, including cell proliferation. We and others have shown that inosine 5’-monophosphate dehydrogenase 2 (IMPDH2), the rate limiting enzyme in the de novo synthesis of GTP, is important in migration and invasion of cancer, including TNBC, however the role it plays in chemoresistance remains to be elucidated. Our preliminary data revealed that IMPDH2 expression levels modulate doxorubicin sensitivity in different TNBC cell lines. Moreover, we have generated MDA-MB-231 cells that are resistant to doxorubicin (referred to as DoxoR), and revealed IMPDH2 to be upregulated in DoxoR cells, at both protein and mRNA levels as well as having higher activity. Consistently, DoxoR cells have ~50% more GTP than their naïve counterpart and, interestingly, are twice more sensitive to treatment with Ribavirin, a well-tolerated FDA approved IMPDH inhibitor, suggesting that Ribavirin could be repurposed for the treatment of chemoresistant TNBC. As expected, RNA sequencing of DoxoR cells revealed increased stemness properties when compared to naïve cells, which we confirmed experimentally in tumor sphere formation assays. Importantly, knockdown of IMPDH2 reverted the ability of DoxoR cells to form bigger tumor spheres, as well as reduced the IC50 of doxorubicin to that of naïve cells. Therefore, our data suggests that increased IMPDH2 and GTP levels in resistant setting could be a potential new vulnerability to be leveraged therapeutically to suppress and/or prevent the growth of chemoresistant lesions. Citation Format: Tatiane da Silva Fernandes, Anna Bianchi-Smiraglia. Novel roles of Inosine Monophosphate Dehydrogenase 2 (IMPDH2) in TNBC doxorubicin resistance [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P6-11-04." @default.
• W4322770501 created "2023-03-03" @default.
• W4322770501 creator A5050138694 @default.
• W4322770501 creator A5090951029 @default.
• W4322770501 date "2023-03-01" @default.
• W4322770501 modified "2023-10-16" @default.
• W4322770501 title "Abstract P6-11-04: Novel roles of Inosine Monophosphate Dehydrogenase 2 (IMPDH2) in TNBC doxorubicin resistance" @default.
• W4322770501 doi "https://doi.org/10.1158/1538-7445.sabcs22-p6-11-04" @default.
• W4322770501 hasPublicationYear "2023" @default.
• W4322770501 type Work @default.
• W4322770501 citedByCount "0" @default.
• W4322770501 crossrefType "journal-article" @default.
• W4322770501 hasAuthorship W4322770501A5050138694 @default.
• W4322770501 hasAuthorship W4322770501A5090951029 @default.
• W4322770501 hasConcept C121608353 @default.
• W4322770501 hasConcept C126322002 @default.
• W4322770501 hasConcept C2776694085 @default.
• W4322770501 hasConcept C2776802502 @default.
• W4322770501 hasConcept C2778033501 @default.
• W4322770501 hasConcept C2779013556 @default.
• W4322770501 hasConcept C2780110267 @default.
• W4322770501 hasConcept C2781303535 @default.
• W4322770501 hasConcept C2911091166 @default.
• W4322770501 hasConcept C38596361 @default.
• W4322770501 hasConcept C502942594 @default.
• W4322770501 hasConcept C530470458 @default.
• W4322770501 hasConcept C71924100 @default.
• W4322770501 hasConcept C86803240 @default.
• W4322770501 hasConcept C96232424 @default.
• W4322770501 hasConcept C98274493 @default.
• W4322770501 hasConceptScore W4322770501C121608353 @default.
• W4322770501 hasConceptScore W4322770501C126322002 @default.
• W4322770501 hasConceptScore W4322770501C2776694085 @default.
• W4322770501 hasConceptScore W4322770501C2776802502 @default.
• W4322770501 hasConceptScore W4322770501C2778033501 @default.
• W4322770501 hasConceptScore W4322770501C2779013556 @default.
• W4322770501 hasConceptScore W4322770501C2780110267 @default.
• W4322770501 hasConceptScore W4322770501C2781303535 @default.
• W4322770501 hasConceptScore W4322770501C2911091166 @default.
• W4322770501 hasConceptScore W4322770501C38596361 @default.
• W4322770501 hasConceptScore W4322770501C502942594 @default.
• W4322770501 hasConceptScore W4322770501C530470458 @default.
• W4322770501 hasConceptScore W4322770501C71924100 @default.
• W4322770501 hasConceptScore W4322770501C86803240 @default.
• W4322770501 hasConceptScore W4322770501C96232424 @default.
• W4322770501 hasConceptScore W4322770501C98274493 @default.
• W4322770501 hasIssue "5_Supplement" @default.
• W4322770501 hasLocation W43227705011 @default.
• W4322770501 hasOpenAccess W4322770501 @default.
• W4322770501 hasPrimaryLocation W43227705011 @default.
• W4322770501 hasRelatedWork W2018180569 @default.
• W4322770501 hasRelatedWork W2154708791 @default.
• W4322770501 hasRelatedWork W2305100815 @default.
• W4322770501 hasRelatedWork W2386717267 @default.
• W4322770501 hasRelatedWork W2591616149 @default.
• W4322770501 hasRelatedWork W2898196535 @default.
• W4322770501 hasRelatedWork W3217390539 @default.
• W4322770501 hasRelatedWork W4283771460 @default.
• W4322770501 hasRelatedWork W4304116770 @default.
• W4322770501 hasRelatedWork W4322770501 @default.
• W4322770501 hasVolume "83" @default.
• W4322770501 isParatext "false" @default.
• W4322770501 isRetracted "false" @default.
• W4322770501 workType "article" @default.